Pharmaceuticals 2014, 7, 311-338; doi:10.3390/ph7030311 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy † Wiebke Sihver 1,*, Jens Pietzsch 1,2, Mechthild Krause 3,4,5,6, Michael Baumann 3,4,5,6, Jörg Steinbach 1,2 and Hans-Jürgen Pietzsch 1 1 Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, Dresden 01328, Germany; E-Mails:
[email protected] (J.P.);
[email protected] (J.S.);
[email protected] (H.-J.P) 2 Department of Chemistry and Food Chemistry, Technische Universität Dresden, Dresden 01062, Germany 3 Department of Radiation Oncology and OncoRay, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden 01307, Germany; E-Mails:
[email protected] (M.K.);
[email protected] (M.B.) 4 OncoRay—National Center for Radiation Research in Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden 01307, Germany 5 German Cancer Consortium (DKTK) Dresden and German Cancer Research Center (DKFZ), Heidelberg 69120, Germany 6 HZDR, Institute of Radiation Oncology, Bautzner Landstraße 400, Dresden 01328, Germany † Dedicated to Prof. Bernd Johannsen (Dresden-Rossendorf) on the occasion of his 75th birthday * Author to whom correspondence should be addressed; E-Mail:
[email protected]; Tel.: +49-351-260-2424; Fax: +49-351-260-3232. Received: 20 December 2013; in revised form: 11 February 2014 / Accepted: 21 February 2014 / Published: 5 March 2014 Abstract: The epidermal growth factor receptor (EGFR) has evolved over years into a main molecular target for the treatment of different cancer entities.